𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma

✍ Scribed by Dr Michelle A. Fanale, Anas Younes

Book ID
119928711
Publisher
Springer International Publishing AG
Year
2007
Tongue
English
Weight
165 KB
Volume
67
Category
Article
ISSN
0012-6667

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of B-cell non-Hodgkin's lympho
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have

The treatment of non-Hodgkin's lymphoma
The treatment of non-Hodgkin's lymphoma
✍ Samuel Hellman; David S. Rosenthal; William C. Moloney; John T. Chaffey 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB 👁 2 views

Much of the approach to evaluation and management of the non-Hodgkin's lymphomas has been modeled after Hodgkin's disease. However, as the name implies, they are quite different. The non-Hodgkin's lymphomas are a group of diseases and syndromes. These many different presentations, syndromes, and pos